Regeneron Pharmaceuticals' Income towards Parent Company rose 8.91% to $1.5 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $4.6 billion, marking a year-over-year decrease of 1.64%. This contributed to the annual value of $4.4 billion for FY2024, which is 11.61% up from last year.
According to the latest figures from FY2024, Regeneron Pharmaceuticals' Income towards Parent Company is $4.4 billion, which was up 11.61% from $4.0 billion recorded in FY2023.
In the past 5 years, Regeneron Pharmaceuticals' Income towards Parent Company registered a high of $8.1 billion during FY2021, and its lowest value of $3.5 billion during FY2020.
Moreover, its 3-year median value for Income towards Parent Company was $4.3 billion (2022), whereas its average is $4.2 billion.
In the last 5 years, Regeneron Pharmaceuticals' Income towards Parent Company surged by 129.86% in 2021 and then slumped by 46.28% in 2022.
Yearly analysis of 5 years shows Regeneron Pharmaceuticals' Income towards Parent Company stood at $3.5 billion in 2020, then surged by 129.86% to $8.1 billion in 2021, then crashed by 46.28% to $4.3 billion in 2022, then decreased by 8.87% to $4.0 billion in 2023, then climbed by 11.61% to $4.4 billion in 2024.

Peer Comparison

Historic Data

Download Data 🔒

Date	Value